<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor (Ki = 4.9 nM) was evaluated in rat models of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> combined with a <z:mp ids='MP_0001914'>bleeding</z:mp> time test and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>After drugs were given by i. v. bolus injection plus a continuous infusion, the ID50, (a dose that exhibits 50% inhibition of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation over each vehicle group) values of AT-1459, argatroban, and dalteparin were 0.04 mg/kg plus 0.04 mg/kg/h, 0.1 mg/kg plus 0.4 mg/ kg/h, and 13.0 IU/kg plus 26.0 IU/kg/h, respectively, in the <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> study </plain></SENT>
<SENT sid="2" pm="."><plain>The BT2 (a dose that causes 2-fold prolongation of <z:mp ids='MP_0001914'>bleeding</z:mp> time over each vehicle group) values of AT-1459, argatroban, and dalteparin were 0.9 mg/kg plus 0.9 mg/kg/h, 1.0 mg/kg plus 0.6 mg/kg/h, and 345.5 IU/kg plus 691.0 IU/kg/h in the rat tail transection model </plain></SENT>
<SENT sid="3" pm="."><plain>The ratios of BT2/ID50 of AT-1459, argatroban, and dalteparin were 22.5, 10.0, and 26.6, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>In a rat model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> induced by topical <z:chebi fb="0" ids="30812">FeCl2</z:chebi> application, intravenous administration of AT-1459, argatroban, and dalteparin improved the vessel patency significantly (P &lt; 0.01) at 0.6 mg/kg plus 0.6 mg/kg/h, 0.6 mg/kg plus 2.4 mg/kg/h, and 300 IU/kg plus 600 IU/kg/h, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The oral antithrombotic effect of AT-1459 lasted for 6 after administering 30 mg/kg and improved the vessel patency significantly 1 h after administering the same dose in venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> models, respectively, with a rapid <z:hpo ids='HP_0003674'>onset</z:hpo> of action </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> also inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight and improved the vessel patency significantly after oral administration of 0.3 mg/kg for three consecutive days in the same study </plain></SENT>
<SENT sid="7" pm="."><plain>The antithrombotic and hemorrhagic effects of <z:hpo ids='HP_0000001'>all</z:hpo> drugs studied were correlated with plasma concentration or clotting times </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that AT-1459 may be clinically useful as an orally available antithrombotic agent for the prevention of venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
</text></document>